Inventiva S.A (IVA) | Financial Analysis & Statements
Inventiva S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2021Income Metrics
Revenue
65.0K
Operating Income
-13.7M
-21,032.31%
Net Income
-14.3M
-21,992.31%
EPS (Diluted)
€-0.37
Balance Sheet Metrics
Total Assets
179.0M
Total Liabilities
187.9M
Shareholders Equity
-8.9M
Cash Flow Metrics
Operating Cash Flow
-24.5M
Free Cash Flow
-12.1M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2021
Inventiva S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | 9.2M | 17.5M | 12.2M | 4.2M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | - | 90.9M | 110.0M | 60.5M | 48.5M |
| Selling, General & Administrative | - | 17.1M | 15.6M | 15.3M | 11.3M |
| Other Operating Expenses | - | -5.5M | -5.7M | -6.9M | -6.5M |
| Total Operating Expenses | 0 | 102.5M | 119.9M | 68.8M | 53.3M |
| Operating Income | - | -94.0M | -102.7M | -56.9M | -51.2M |
| Operating Margin % | 0.0% | -1,021.8% | -587.4% | -466.8% | -1,220.2% |
| Non-Operating Items | |||||
| Interest Income | - | 1.1M | 991.0K | 390.0K | 57.0K |
| Interest Expense | - | 12.2M | 5.2M | 707.0K | 138.0K |
| Other Non-Operating Income | - | -78.8M | -2.9M | 2.9M | 2.0M |
| Pre-tax Income | - | -183.9M | -109.8M | -54.3M | -49.3M |
| Income Tax | - | 313.0K | 607.0K | -20.0K | 364.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | - | -184.2M | -110.4M | -54.3M | -49.6M |
| Net Margin % | 0.0% | -2,002.8% | -631.8% | -445.6% | -1,183.6% |
| Key Metrics | |||||
| EBITDA | - | -88.0M | -101.1M | -54.8M | -50.9M |
| EPS (Basic) | €-1.90 | €-3.08 | €-2.43 | €-1.31 | €-1.27 |
| EPS (Diluted) | €-1.90 | €-3.08 | €-2.43 | €-1.31 | €-1.27 |
| Basic Shares Outstanding | 186388421 | 59778701 | 45351799 | 41449732 | 39168152 |
| Diluted Shares Outstanding | 186388421 | 59778701 | 45351799 | 41449732 | 39168152 |
Income Statement Trend
Inventiva S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 96.6M | 26.9M | 86.7M | 86.6M | 105.7M |
| Short-term Investments | 0 | 70.0K | 1.0M | 8.8M | 7.3M |
| Accounts Receivable | 531.0K | 3.8M | 0 | 4.0M | 48.0K |
| Inventory | 0 | 417.0K | 373.0K | 392.0K | 320.0K |
| Other Current Assets | 349.0K | 422.0K | 282.0K | 763.0K | 1.0M |
| Total Current Assets | 111.5M | 48.2M | 106.4M | 115.6M | 133.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 10.7M | 10.5M | 6.8M | 1.6M | 1.2M |
| Goodwill | 48.0K | 542.0K | 568.0K | 770.0K | 935.0K |
| Intangible Assets | 48.0K | 542.0K | 568.0K | 770.0K | 935.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 217.0K | 225.0K | 65.0K | -2.0K | - |
| Total Non-Current Assets | 7.5M | 21.4M | 9.6M | 6.4M | 5.9M |
| Total Assets | 119.0M | 69.6M | 116.0M | 122.0M | 138.9M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 32.9M | 37.7M | 19.4M | 14.6M | 6.9M |
| Short-term Debt | 5.9M | 5.3M | 5.9M | 1.3M | 18.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 73.4M | - | -1.0K | 1.0K | - |
| Total Current Liabilities | 120.7M | 50.2M | 30.7M | 22.9M | 13.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 48.5M | 32.2M | 28.7M | 8.8M | 10.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 30.2M | 7.4M | -2.0K | -2.0K | 1.0K |
| Total Non-Current Liabilities | 104.9M | 51.4M | 39.8M | 10.3M | 13.8M |
| Total Liabilities | 225.6M | 101.6M | 70.5M | 33.1M | 27.7M |
| Equity | |||||
| Common Stock | 957.0K | 521.0K | 421.0K | 409.0K | 386.0K |
| Retained Earnings | -184.2M | -110.4M | -54.3M | -49.6M | -33.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -106.6M | -32.0M | 45.5M | 88.9M | 111.2M |
| Key Metrics | |||||
| Total Debt | 54.3M | 37.5M | 34.5M | 10.1M | 10.1M |
| Working Capital | -9.2M | -2.0M | 75.7M | 92.7M | 119.1M |
Balance Sheet Composition
Inventiva S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -184.2M | -110.4M | -54.3M | -49.6M | -33.6M |
| Depreciation & Amortization | 5.2M | 2.6M | 1.7M | -1.3M | 1.9M |
| Stock-Based Compensation | 3.6M | 4.0M | 2.2M | 2.1M | 938.0K |
| Working Capital Changes | 5.0M | -2.7M | 2.2M | -6.6M | -3.2M |
| Operating Cash Flow | -87.4M | -109.1M | -52.4M | -58.0M | -43.3M |
| Investing Activities | |||||
| Capital Expenditures | -333.0K | -409.0K | -520.0K | -445.0K | -292.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | -8.3M | -1.0K | -1.3M | -8.3M |
| Investment Sales | 9.1M | 978.0K | 9.4M | - | - |
| Investing Cash Flow | 8.7M | -7.7M | 8.9M | -1.8M | -8.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 24.9M | 0 | 30.2M | 0 | 10.0M |
| Debt Repayment | -5.0M | -4.1M | -1.8M | -28.0K | -87.0K |
| Financing Cash Flow | 87.4M | 29.1M | 67.5M | 25.4M | 121.7M |
| Free Cash Flow | -86.3M | -82.2M | -45.5M | -48.2M | -30.9M |
| Net Change in Cash | 8.7M | -87.8M | 24.0M | -34.3M | 69.8M |
Cash Flow Trend
Inventiva S.A Key Financial Ratios
No financial ratio data available.
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| Abivax SA | 7.6B | -19.88 | 16.56 | -135.58% | 0.00% | 7.05 |
| Nanobiotix | 1.4B | - | - | 28.36% | -73.52% | -1.13 |
| Medincell S.A | 831.6M | -37.35 | - | 112.65% | -61.49% | -2.40 |
| BNP Paribas Easy | 527.3M | 22.65 | - | -96.39% | -27.22% | 2.22 |
| Valneva SE | 416.1M | 70.64 | 3.91 | -80.16% | -65.95% | 195.21 |
Financial data is updated regularly. All figures are in the company's reporting currency.